Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sikkerhed og effektivitet af venstre bundtgrenområde tempo versus konventionel hjerte -resynkroniseringsterapi i hjertesvigt (SYNCHRONICITY)

2. november 2026 opdateret af: Boston Scientific Corporation

This study will compare two different methods to pace the heart to treat heart failure including:

  1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
  2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

850

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alabama
      • Huntsville, Alabama, Forenede Stater, 35801
        • Rekruttering
        • Heart Center Research, LLC
        • Kontakt:
          • John Jennings, Dr.
        • Ledende efterforsker:
          • John Jennings, Dr.
      • Mobile, Alabama, Forenede Stater, 36608
        • Rekruttering
        • Mobile Infirmary Medical Center
        • Kontakt:
          • Ernest Matthew Quin, Dr.
        • Ledende efterforsker:
          • Ernest Matthew Quin, Dr.
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85054
        • Rekruttering
        • Mayo Clinic Phoenix
        • Kontakt:
          • Mayank Sardana, MD
        • Ledende efterforsker:
          • Mayank Sardana, MD
    • Arkansas
      • Jonesboro, Arkansas, Forenede Stater, 72401
        • Rekruttering
        • Arrhythmia Research Group
        • Kontakt:
          • Devi Nair, Dr.
        • Ledende efterforsker:
          • Devi Nair, Dr.
    • California
      • La Jolla, California, Forenede Stater, 92037
        • Rekruttering
        • Scripps Memorial Hospital
        • Kontakt:
          • Nicolas Olson, MD
        • Ledende efterforsker:
          • Nicolas Olson, MD
      • Los Angeles, California, Forenede Stater, 90048
        • Rekruttering
        • Cedars Sinai Medical Center
        • Ledende efterforsker:
          • Ashkan Ehdaie, MD
        • Kontakt:
          • Ashkan Ehdaie, MD
      • Oakland, California, Forenede Stater, 94609
        • Rekruttering
        • Alta Bates Summit Medical Center
        • Kontakt:
          • Rajan Shah, Dr.
        • Ledende efterforsker:
          • Rajan Shah, Dr.
      • Santa Monica, California, Forenede Stater, 90404
        • Rekruttering
        • Pacific Heart Institute
        • Kontakt:
          • Stephen Tang, MD
        • Ledende efterforsker:
          • Stephan Tang, MD
      • Torrance, California, Forenede Stater, 90505
        • Rekruttering
        • Torrance Medical Center
        • Ledende efterforsker:
          • Gene Kim, MD
        • Kontakt:
          • Gene Kim, MD
      • Ventura, California, Forenede Stater, 93003
        • Rekruttering
        • Cardiology Associates Medical Group, Inc.
        • Kontakt:
          • Jonathan Dukes, Dr.
        • Ledende efterforsker:
          • Jonathan Dukes, Dr.
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Rekruttering
        • Washington Hospital Center
        • Kontakt:
          • Cyrus Hadadi, MD
        • Ledende efterforsker:
          • Cyrus Hadadi, MD
    • Florida
      • Sarasota, Florida, Forenede Stater, 34239
        • Rekruttering
        • Sarasota Memorial Hospital
        • Kontakt:
          • Antonio Moretta, Dr.
        • Ledende efterforsker:
          • Antonio Moretta, Dr.
      • Tampa, Florida, Forenede Stater, 33613
        • Rekruttering
        • AdventHealth Tampa
        • Ledende efterforsker:
          • Kenneth Yamamura, MD
        • Kontakt:
          • Kenneth Yamamura, MD
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30309
        • Rekruttering
        • Piedmont Hospital
        • Kontakt:
          • Kavita Krishnasamy, MD
        • Ledende efterforsker:
          • Kavita Krishnasamy, MD
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Hospital
        • Kontakt:
          • Anand Shah, MD
        • Ledende efterforsker:
          • Anand Shah, MD
    • Idaho
      • Meridian, Idaho, Forenede Stater, 83642
        • Rekruttering
        • St. Luke's Idaho Cardiology Associates
        • Kontakt:
          • Justice Oranefo, MD
        • Ledende efterforsker:
          • Justice Oranefo, MD
    • Illinois
      • Hinsdale, Illinois, Forenede Stater, 60521
        • Rekruttering
        • University of Chicago
        • Kontakt:
          • Shrinath Yeshwant, MD
        • Ledende efterforsker:
          • Shrinath Yeshwant, MD
      • Naperville, Illinois, Forenede Stater, 60540
        • Trukket tilbage
        • Midwest Cardiovascular Institute
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46250
        • Rekruttering
        • Community Heart and Vascular Hospital
        • Kontakt:
          • Krishna Malineni, MD
        • Ledende efterforsker:
          • Krishna Malineni, MD
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • University of Iowa Hospitals and Clinics
        • Ledende efterforsker:
          • Paari Dominic, MD
        • Kontakt:
          • Paari Dominic, MD
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40207
        • Rekruttering
        • Baptist Hospital East Louisville
        • Ledende efterforsker:
          • Kevin Parrott, MD
        • Kontakt:
          • Kevin Parrott, MD
    • Massachusetts
      • Fall River, Massachusetts, Forenede Stater, 02720
        • Rekruttering
        • Southcoast Physicians Group
        • Kontakt:
          • Arnoldas Giedrimas, MD
        • Ledende efterforsker:
          • Arnoldas Giedrimas, MD
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • University of Michigan Hospitals
        • Ledende efterforsker:
          • Thomas Crawford, MD
        • Kontakt:
          • Thomas Crawford, MD
      • Grand Rapids, Michigan, Forenede Stater, 49525
        • Rekruttering
        • Corewell Health
        • Kontakt:
          • Jawad Wassim, MD
        • Ledende efterforsker:
          • Jawad Wassim, MD
    • Minnesota
      • Duluth, Minnesota, Forenede Stater, 55805
        • Trukket tilbage
        • St. Mary's Duluth Clinic Regional Heart Center
      • Saint Cloud, Minnesota, Forenede Stater, 56303
        • Trukket tilbage
        • Centracare Heart and Vascular Center
    • New Jersey
      • Morristown, New Jersey, Forenede Stater, 07932
        • Rekruttering
        • Morristown Medical Center
        • Kontakt:
          • Michael Katz, MD
        • Ledende efterforsker:
          • Michael Katz, MD
    • New York
      • Albany, New York, Forenede Stater, 12211
        • Rekruttering
        • Capital Cardiology Associates
        • Kontakt:
          • Rizwan Alimohammad, MD
        • Ledende efterforsker:
          • Rizwan Alimohammad, MD
      • Flushing, New York, Forenede Stater, 11355
        • Rekruttering
        • New York Hospital Queens
        • Kontakt:
          • Seth Goldbarg, Dr.
        • Ledende efterforsker:
          • Seth Goldbarg, Dr.
      • New York, New York, Forenede Stater, 10021
        • Rekruttering
        • Weill Cornell Medical University
        • Kontakt:
          • Jim Cheung, Dr.
        • Ledende efterforsker:
          • Jim Cheung, Dr.
      • New York, New York, Forenede Stater, 14621
        • Rekruttering
        • Rochester General Hospital
        • Kontakt:
          • Dmitry Chuprun, MD
        • Ledende efterforsker:
          • Dmitry Chuprun, MD
      • Syracuse, New York, Forenede Stater, 13057
        • Rekruttering
        • SUNY-Upstate Medical University
        • Kontakt:
          • Jorge Romero, MD
        • Ledende efterforsker:
          • Jorge Romero, MD
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Rekruttering
        • Sanger Heart and Vascular Institute
        • Kontakt:
          • Navid Nafissi, MD
        • Ledende efterforsker:
          • Navid Nafissi, MD
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Kontakt:
          • Daniel Friedman, MD
        • Ledende efterforsker:
          • Daniel Friedman, MD
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43219
        • Rekruttering
        • Mount Carmel Health System
        • Kontakt:
          • Kamel Addo, MD
        • Ledende efterforsker:
          • Kamel Addo, MD
      • Columbus, Ohio, Forenede Stater, 43214
        • Rekruttering
        • OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
        • Kontakt:
          • Anish Amin, MD
        • Ledende efterforsker:
          • Anish Amin, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Penn Presbyterian Medical Center
        • Kontakt:
          • John Bullinga, MD
        • Ledende efterforsker:
          • John Bullinga, MD
      • Wilkes-Barre, Pennsylvania, Forenede Stater, 18702
        • Rekruttering
        • Geisinger Wyoming Valley
        • Ledende efterforsker:
          • Pugazhendhi Vijayaraman, MD
        • Kontakt:
          • Pugazhendhi Vijayaraman, MD
    • South Dakota
      • Sioux Falls, South Dakota, Forenede Stater, 57108
        • Rekruttering
        • Avera Heart Hospital of South Dakota
        • Kontakt:
          • Christopher Stanton, Dr.
        • Ledende efterforsker:
          • Christopher Stanton, Dr.
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37205
        • Rekruttering
        • St.Thomas Health
        • Kontakt:
          • Ricardo Lugo, MD
        • Ledende efterforsker:
          • Ricardo Lugo, MD
    • Texas
      • Plano, Texas, Forenede Stater, 75093
        • Rekruttering
        • Heart Hospital Baylor Plano
        • Kontakt:
          • Mustafa Dohadwala, MD
        • Ledende efterforsker:
          • Mustafa Dohadwala, MD
      • Tyler, Texas, Forenede Stater, 75701
        • Rekruttering
        • Christus Trinity Mother Frances Health System
        • Kontakt:
          • Stanislov Weiner, Dr.
        • Ledende efterforsker:
          • Stanislov Weiner, Dr.
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22908
        • Rekruttering
        • University of Virginia Medical Center
        • Ledende efterforsker:
          • Pamela Mason, MD
        • Kontakt:
          • Pamela Mason, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law

  2. Patient meets a guideline-based indication for a de novo CRT-D device

  3. Primary prevention indication for ICD therapy

  4. Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)

  5. NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months

    *GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications

  6. Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment

  7. Patient is willing to participate in LATITUDE™ NXT remote patient monitoring

  8. Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)

  9. Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)

Exclusion Criteria:

  1. Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
  2. Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
  3. Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
  4. Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
  5. Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
  6. Prior or planned mechanical or bioprosthetic tricuspid valve replacement
  7. Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
  8. Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
  9. History of heart transplantation or left ventricular assist device (LVAD) implantation
  10. Less than 1 year of life expectancy at the time of enrollment
  11. Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
  12. History of ventricular septal defect (VSD)
  13. Complex congenital heart disease
  14. Documented diagnosis of cardiac amyloidosis
  15. Known occlusion or other reason limiting central venous access for transvenous leads
  16. Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
  17. Patient currently requiring dialysis
  18. Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
  19. Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
  20. Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
  21. Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: CRT Cohort

Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort.

Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead.

Eksperimentel: LBBA Cohort

Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort.

Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Tidsramme: Through study completion, up to maximum of 5 years

The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.

Through study completion, up to maximum of 5 years
System-related complication-free rate
Tidsramme: 12 months

The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal

12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Win ratio composite assessment
Tidsramme: Through study completion, up to a maximum of 5 years

Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life

Through study completion, up to a maximum of 5 years
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Tidsramme: Through study completion, up to a maximum of 5 years

The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.

Through study completion, up to a maximum of 5 years
System-related complication-free rate between randomized arms
Tidsramme: 12 months

System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms.

12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. oktober 2025

Primær færdiggørelse (Anslået)

1. november 2029

Studieafslutning (Anslået)

1. november 2029

Datoer for studieregistrering

Først indsendt

23. juni 2025

Først indsendt, der opfyldte QC-kriterier

7. juli 2025

Først opslået (Faktiske)

17. juli 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner